Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Marzilli, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marzilli, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Trimetazidine: a metabolic agent for the treatment of stable angina

M. Marzilli*

Cardiothoracic Department, University of Pisa, Pisa, Italy

* Correspondence: M. Marzilli, Cardiothoracic Department, University of Pisa, Via Paradisa, 2 56100 Pisa, Italy.

Abstract

It has been recently demonstrated that trimetazidine, known for years to be an effective antianginal agent, shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. By decreasing fatty acid oxidation, trimetazidine stimulates glucose utilization, restoring coupling between glycolysis and carbohydrate oxidation and leading to adenosine triphosphate production with lesser oxygen consumption. The antianginal properties of this agent are independent of haemodynamic changes, and dramatically improve recovery of mechanical function after ischaemia. Several studies have tested the efficacy of trimetazidine and have demonstrated this agent to be at least as effective as and better tolerated than haemodynamic agents. In stable effort angina, trimetazidine improves exercise tolerance and elevates the ischaemic threshold to an extent comparable with beta-blockers and calcium channel blockers. The combination of trimetazidine and a beta-blocker appears more effective than the combination of nitrates and a beta-blocker, and the addition of trimetazidine improves symptoms in patients resistant to diltiazem. The cardioprotective effects of trimetazidine have been recently confirmed in human ischaemia-reperfusion, including patients undergoing percutaneous coronary artery revascularization and bypass surgery with cardioplegic arrest. A new modified-release (MR) formulation of trimetazidine will shortly be introduced. A twice-daily regimen of these new MR tablets has been shown to be bioequivalent to the thrice-daily regimen of the previous formulation, and has been clinically tested in patients with stable angina pectoris resistant to beta-blockers. In a multicentre, international, double-blind, randomized, placebo-controlled study, the addition of trimetazidine MR tablets twice daily to atenolol 50 mg significantly prolonged the time to 1 mm ST depression and the time to onset of angina, with a favourable safety profile. The clinical safety of this new formulation has been confirmed in a double-blind, placebo-controlled study enrolling 234 elderly patients treated for 1 year. Safety and efficacy of trimetazidine MR promise to expand the role of metabolic agents for the treatment of ischaemic heart disease.

Key Words: Medical therapy • stable angina • trimetazidine

References

  1. Thadani U. Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol. 1997;79:24–30
  2. Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. J Am Coll Cardiol. 1996;27:311–316[Abstract]
  3. Fox KM, Mulgahy D, Findlay I, Ford I, Dargie HJTIBET Study Group. The Total Ischemic Burden European Trial (TIBET). on behalf of theEur Heart J. 1996;17:96–103[Abstract/Free Full Text]
  4. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet. 1991;338:1036–1039[CrossRef][Web of Science][Medline]
  5. Boddeke E, Hugtenberg J, Jap W, Heynij J, van Zwiten PA. New anti-ischemic drugs: cytoprotective action with no primary haemodynamic effects. Trends Pharmacol Sci. 1989;10:397–400[CrossRef][Medline]
  6. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588[Abstract/Free Full Text]
  7. Stanley WC. Cardiac energetics during ischemia and the rationale for metabolic interventions. Coron Artery Dis. 2001;12(suppl 1):S3–S7
  8. Lopaschuck GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 2001;12(suppl 1):S8–S11
  9. Williams FM, Tanda K, Kus M, William TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993;22:828–833[Web of Science][Medline]
  10. Levanchy N, Martin J, Rossi A. Anti-ischemic effects of Trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther. 1987;286:97–110[Web of Science][Medline]
  11. Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg. 1992;33:486–491[Medline]
  12. Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine. Am J Cardiol. 1995;76:41B–44B[CrossRef][Medline]
  13. Drake-Holland AJ, Belcher PR, Hynd J, Noble IM. Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine. Basic Res Cardiol. 1993;88:250–258[Web of Science][Medline]
  14. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol. 1993;21:128–135[Web of Science][Medline]
  15. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992;13:1109–1115[Abstract/Free Full Text]
  16. Sellier P, Audouin P, Payen B, Corona P, Duong TC, Ourbak P. Acute effects of trimetazdine evaluated by exercise testing. Eur J Clin Pharmacol. 1987;33:205–207[CrossRef][Web of Science][Medline]
  17. Detry JM. Clinical features of an anti-anginal drug in angina pectoris. Eur Heart J. 1993;14:18–24[Abstract/Free Full Text]
  18. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. [in French]Arch Mal Coeur Vaiss. 1986;9:1331–1336
  19. Passeron J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study. [in French]Presse Med. 1986;35:1775–1778
  20. Dalla Volta S, Maraglino G, Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind crossover study. Cardiovasc Drugs Ther. 1990;4:853–860
  21. Détry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994;37:279–288[Web of Science][Medline]
  22. Monpère C, Brochier M, Demange J, Ducloux G, Warin JF. Combination of trimetazidine with nifedipine in effort angina. Cardiovasc Drugs Ther. 1990;4:824–825
  23. Michaelides AP, Vyssoulis GP, Bonoris PE, Psaros TK, Papadopoulos PD, Toutouzas PK. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res. 1989;46:565–576
  24. Michaelides AP, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest. 1997;13:8–14
  25. Levy Sgroup of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol. 1995;76:12B–16B[CrossRef][Medline]
  26. Manchanda SC, Krishnawami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart. 1997;78:353–357[Abstract/Free Full Text]
  27. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment of stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J. 2001;: (in press)
  28. Szwed H, Pachoki R, Domnzal-Bochenska M, et al. The anti-ischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I. Cardiovasc Drugs Ther. 1999;13:215–220

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Marzilli, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marzilli, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?